Welcome to our dedicated page for Paychex SEC filings (Ticker: PAYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Paychex, Inc. filings document formal disclosures for its human capital management business, including quarterly operating results furnished on Form 8-K, credit facility amendments, capital-return authorizations, and governance changes involving directors and senior officers.
The company's proxy materials and annual-meeting reports address board elections, executive compensation votes, auditor ratification, committee matters, and stockholder voting outcomes. Its filings also describe common-stock repurchase authority, revolving credit facilities, covenant changes, and formal reporting for payroll, HCM, HR Solutions, PEO, ASO, benefits, retirement, and insurance services.
Paychex, Inc. (PAYX) filed a Form 4 showing a director received an equity grant on 10/15/2025. The filing reports the award of 725 restricted stock units at a price of $0, pursuant to the Amended and Restated 2002 Stock Incentive Plan.
The director also received a new stock option for 3,061 shares with an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035. Following these transactions, the director beneficially owned 2,800 shares directly. The filing also lists previously awarded options, including 5,082 at $120.86 (expiring 07/14/2033), 3,351 at $121.63 (expiring 07/14/2034), and 670 at $140.68 (expiring 07/14/2035).
Paychex (PAYX) Form 4: A director reported equity awards on 10/15/2025. The filing shows an award of 725 shares of common stock at a price of $0, noted as restricted stock units subject to vesting. Following this, 889 shares were beneficially owned directly, and 23,758 shares were beneficially owned indirectly through the Joseph G. Doody Revocable Living Trust. A stock option for 3,061 shares was granted at an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035.
Paychex (PAYX) reported an insider transaction by its President and CEO. On 10/15/2025, the executive disposed of 624 shares of common stock at $127.52 per share, coded “F”.
According to the footnote, the shares were withheld to satisfy tax obligations arising from the vesting of restricted stock units. Following the transaction, the executive directly holds 81,131 shares of Paychex common stock.
Paychex (PAYX) reported insider activity. A reporting person who is a Director and Chairman received 855 restricted stock units on 10/15/2025 at a price of $0 under the Amended and Restated 2002 Stock Incentive Plan. The person also received a stock option for 3,607 shares with an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035.
Following these transactions, the filer reported 426,324.3318 shares beneficially owned, held directly. The filing also lists previously granted option awards with various exercise prices and expiration dates.
Paychex (PAYX) reported an insider Form 4 for a company officer (VP, Controller & Treasurer). On 10/15/2025, the officer disposed of 38 shares of common stock at $127.52 under code F, reflecting shares withheld to cover taxes from restricted stock units vesting. Following this transaction, the officer beneficially owns 5,389 shares directly.
The filing also lists outstanding stock options, including 7,310 options at an exercise price of $140.68 (exercisable 07/15/2026; expiration 07/14/2035).
Paychex Inc. (PAYX) director reported equity awards. On 10/15/2025, the insider acquired 725 shares of common stock at $0, described as an award of restricted stock units subject to vesting. Following this, the insider beneficially owned 8,254 shares directly. The filing also shows a new stock option grant for 3,061 shares at an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035, alongside previously granted options with various terms.
Paychex, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on October 09, 2025 via live webcast. Holders of 322,916,274 shares of common stock were present in person or by proxy.
All ten director nominees were elected to one-year terms. The non-binding advisory vote on named executive officer compensation was approved with 275,491,813 votes for, 10,038,236 against, and 1,115,043 abstentions, with 36,271,182 broker non-votes.
Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026, with 318,217,078 votes for, 4,314,110 against, and 385,086 abstentions.
The Vanguard Group filed Amendment No. 9 to Schedule 13G reporting a passive stake in Paychex, Inc. (PAYX). Vanguard disclosed beneficial ownership of 37,764,731 shares of Paychex common stock, representing 10.5% of the class as of 09/30/2025.
The filing shows 0 shares with sole voting power and 1,925,025 shares with shared voting power. Vanguard reports 34,607,727 shares with sole dispositive power and 3,157,004 shares with shared dispositive power. Vanguard certified the securities were acquired and are held in the ordinary course of business and not to change or influence control.
Adam Brooks, identified as Sr. Vice President, Paycor and an officer of Paychex Inc. (PAYX), reported a transaction dated 10/01/2025 in which he disposed of 8,902 shares of Paychex common stock at a price of $124.01. The filing states this disposition was to satisfy tax withholding obligations arising from the lapse of restrictions on restricted stock/RSUs. After the sale Mr. Brooks beneficially owns 59,603 shares. The Form 4 also shows Mr. Brooks holds 14,767 stock options with an exercise price of $140.68, exercisable beginning 07/15/2026 and expiring 07/14/2035.
Paychex Inc. (PAYX) reporting person Ryan Norman Bergstrom, Chief Product Officer, disposed of 6,781 shares of Paychex common stock on 10/01/2025 at a price of $124.01 per share to satisfy tax withholding arising from the lapse of restricted stock/RSU restrictions. After the disposition the reporting person beneficially owns 46,484 shares directly. The filing also shows a stock option position with a $140.68 exercise price covering 14,767 underlying shares that become exercisable on 07/15/2026 and expire on 07/14/2035. The Form 4 was executed by an attorney-in-fact on 10/03/2025.